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Background: Recent research displays that breast cancer (BC) is a heterogeneous disease and distinct molecular
subtypes yield different prognostic outcomes.
Methods: We conducted a meta-analysis to clarify the role of molecular subtypes in recurrence risk after
breast-conserving therapy (BCT). Eligible studies of single- (ER, PR, Her-2, and p53) and triple-molecular (Luminal A,
Luminal B, Her-2, triple-negative) subtypes were identified through multiple search strategies. Pooled hazard ratios
with 95% confidence intervals were calculated to assess this research topic.
Results: Fifteen studies involving 21,645 participants were included in the meta-analysis. Her-2 positive patients
had a significantly higher recurrence risk in both overall merge (HR = 1.97, 95% CI: 1.41-2.75) and subtotal merge of
local recurrence (LR) (HR = 1.93, 95% CI: 1.34-2.78). Significantly higher risk of recurrence was also observed in p53
positive patients by overall merge (HR = 1.78, 95% CI: 1.49 -2.12) and subtotal merge of LR (HR = 1.73, 95% CI:
1.44-2.07). When setting Luminal A as a baseline, Luminal B, Her-2, and triple-negative all showed significantly
increased risk for both LR and distant recurrence (DR). Comparing triple-negative and non-triple-negative subtypes
showed the biggest risk for overall recurrence (HR = 3.19, 95% CI: 1.91-5.31) and LR (HR = 3.31, 95% CI: 1.69-6.45).
Conclusions: Our meta-analysis showed significant differences in recurrence risk among various molecular subtypes
after BCT. Although Her-2 and p53 positive subtypes can be considered independent prognostic biomarkers for
indicating high LR risk, triple-molecular biomarkers showed higher clinical value. Triple-negative subtype showed
the highest recurrence risk among all subtypes, and adjuvant chemotherapy should be considered for it.
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Breast-conserving therapy (BCT) is considered the stand-
ard treatment for early-stage breast cancer (BC) [1-3].
Though patients who undergo breast-conserving surgery
(BCS) have a better quality of life and equivalent survival
compared with those undergoing mastectomy [3], many
randomized trials consistently demonstrate a measur-
able increased risk of local recurrence (LR) after BCS* Correspondence: ws0801@hotmail.com
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unless otherwise stated.when compared to mastectomy [4-6], estimated at 1%
per year [3,7-10].
The factors affecting recurrence are complex, including
clinical and histological characteristics, with or without
postoperative adjuvant radiotherapy and systemic therapy
(chemotherapy and/or hormone therapy) [11]. Recent re-
searches display that BC is a heterogeneous disease [12]
and distinct molecular subtypes yield different prognostic
outcomes [13-19]. These molecular markers mainly in-
clude estrogen receptor (ER), progesterone receptor (PR),
human epidermal growth factor receptor 2 (HER-2), p53,
and Ki67 [14,20]; these have immensely contributed to the
selection of the optimal strategy for BCT [21-23]. How-
ever, the impact of molecular subtypes on LR or distanttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Therefore, we conducted a meta-analysis to clarify the role
of molecular subtypes in BC recurrence after BCT.
Methods
Search strategy
Original articles analyzing the hazard ratio (HR) of re-
currence after BCT in different BC molecular subtypes
were searched by online databases PubMed, Embase,
and Web of Science. We selected studies carefully by the
following sets of key words variably combined: ‘breast
cancer’, ‘breast-conserving surgery’, ‘breast-conserving
therapy’, ‘recurrence’, ‘hazard ratio’, ‘molecular marker’,
and ‘molecular subtype’; the last search update was per-
formed on 10 January 2014. All eligible studies published
in English were reviewed, and their bibliographies were
also examined for other relevant publications. Relevant
review articles were manually searched to find additional
eligible studies. If more than one article was published
using the same series of study subjects, we only chose
the latest or most complete study for this meta-analysis.
All the studies enrolled in this meta-analysis have been
performed with the approval of an appropriate ethics
committee. Researches carried out on humans are all in
compliance with the Helsinki Declaration.
Inclusion and exclusion criteria
We followed the guidelines of the critical checklist pro-
posed by the Dutch Cochrane Centre Meta-analysis ofFigure 1 Flow diagram of study selection process.Observational Studies in Epidemiology (MOOSE) [24].
Articles were identified as eligible when they fit the fol-
lowing criteria: (1) they performed BCS on BC patients;
(2) they focused on postoperative recurrence; (3) they in-
vestigated the association between recurrence and differ-
ent BC molecular subtypes. Altogether, 953 studies were
excluded by exclusion criteria and further quality evalu-
ation that are presented in Figure 1.Data extraction
All data were carefully extracted from eligible publica-
tions in duplicate by two co-authors (PJ and JZ). Any
disagreements were resolved by discussion between the
two authors. The extracted data elements in Table 1 in-
clude the followings: first author’s last name, publication
year, case nationality, dominant ethnicity, study design,
number of cases, median time to follow-up, percentage
of patients who received adjuvant radiotherapy (RT),
percentage of patients who received adjuvant systemic
therapy (AST), types of recurrence, source of HR, and
characteristics of enrolled cases.
The extracted data elements in Table 2 show the HRs
and 95% confidence intervals (CIs) of different recur-
rences among molecular subtypes. If HR was not re-
ported directly, data were extracted from Kaplan-Meier
curves of survival outcomes to extrapolate required data
using the previously described methods [25-27]. We also
wrote emails to the corresponding authors of enrolled





















Hattangadi [30] USA Caucasian R 1,223 70 100 77.0 46.0 TR Reported IBC, pT1-2 N0-3
Zauls [31] USA Caucasian P 459 45 100 Total 62.1 LF DE DCIS or IBC, tumor size
≤3 cm, positive LNs ≤3
Han [32] Canada Caucasian R 180 104.4 30.6 NM NM LR Reported DCIS with or without
microinvasion
Millar [33] Australia Caucasian P 498 64 100 49.0 38.0 LRR/IBTR/DM DE IBC
Moran [34] USA Caucasian R 368 78 100 49.0 36.0 LR DE IBC, stage I-II, LN (+),
margin (-)
Wong [35] Singapore Asian R 541 72 100 68.0 36.0 LR/DM Reported IBC, LN (-)
Kim [36] Korea Asian P 1,589 61 100 71.8 66.4 IBTR Reported IBC, tumor size ≤5 cm,
age >40 years
Bantema [37] Netherlands Caucasian R 752 41 100 38.7 35.4 LR/DM Reported IBC, stages I-III
Arvold [38] USA Caucasian R 1,434 85 100 Total 91.0 LR Reported IBC, stage I-II
Truong [39] Canada Caucasian R 5,688 71.7 100 36.6 26.7 LR/RR/LRR Reported IBC, pT1-2, positive
LNs ≤3, M0
Sharon [40] Canada Caucasian R 133 107 0.0 NM NM LR Reported DCIS, margin (-)
Roos [41] Netherlands Caucasian R 39 39 51.3 0.0 NM LR DE DCIS
Yau [42] China Asian R 605 64.8 100 74.0 45.0 IBTR/DF Reported IBC, T1-2
Smith [43] USA Caucasian R 8,724 60 73.0 NM 3.0 SIBC Reported IBC, age ≥70 years,
tumor size ≤2 cm, LN (-)
Silvestrini [44] Spain Caucasian R 635 72 78.1 0.0 0.0 LR Reported Resectable breast
cancer, N0, M0
Study design is described as either prospective (P) or retrospective (R).
Radiotherapy (RT) is defined as accelerated partial breast irradiation (APBI), whole breast irradiation (WBI) or MammoSite brachytherapy (MB).
Adjuvant systemic therapy (AST) is defined as hormone/endocrine therapy (HT) only, chemotherapy (CT) only, or both.
Abbreviations: m month HR hazard ratio, NM not mentioned, TR true recurrence, LF local failure, LR local recurrence or relapse, LRR locoregional recurrence;
IBTR ipsilateral breast tumor recurrence, DM distant metastasis, RR regional recurrence, DF distant failure, SIBC second ipsilateral breast cancer, DE dataextrapolated
IBC invasive breast cancer, DCIS ductal carcinoma in situ, LN lymph node.
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data needed for the meta-analysis.Statistical analysis
All statistical analyses were conducted using Stata (ver-
sion 11.0; StataCorp LP, College Station, TX, USA) and
Excel (version 2007; Microsoft Corp., WA, USA). The
aggregation of HRs and 95% CIs were calculated follow-
ing Tierney’s method [27]. Forrest plots were used to es-
timate the effect of different molecular subtypes on
recurrence after BCT. The heterogeneity assumption of
pooled HRs was verified by Cochran’s Q-test, and the
percentage of Higgins’ I-squared statistic (I2) was used
to quantify the extent of heterogeneity explained by
these characteristics of enrolled studies. If significant
heterogeneity was observed (P <0.1 or I2 >50%), a
random-effects model (Der Simonian- Laird method)
was applied; otherwise, the fixed-effects model (Mantel-
Haenszel method) was adopted [28]. Potential publica-
tion bias was determined by Egger’s linear regression test
with a funnel plot [29].To avoid the influence of heterogeneity among these
studies, we also conducted a subgroup analysis stratified
by different recurrence categories (LR and DR). We de-
fined LR to include true recurrence, local failure, local re-
currence or relapse, ipsilateral breast tumor recurrence,
locoregional recurrence, and second ipsilateral BC. DR
was defined as distant metastasis or failure, and recur-
rence was defined as any of LR and/or DR, the merger of
LR and DR in the same study or not definitely mentioned.
All P values were two-sided and a P value less than 0.05
was considered to be statistically significant.
Results
Summary of included studies
Fifteen studies involving 21,645 participants finally met
the inclusion criteria [30-44]. The main features of eli-
gible studies are summarized in Table 1. These studies
collect data from the United States, Canada, Australia,
Singapore, Korea, the Netherlands, China, and Spain.
The dominant ethnicity of 13 enrolled studies is Caucasian
[30-34,37-41,43,44], with only three studies executed in
Asians [35,36,42]. Most enrolled studies are retrospective





LB vs. LA Her-2 vs. LA TN vs. LA TN vs. non-TN ER - vs. + PR - vs. + Her-2 + vs. - p53 + vs. -
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Hattangadi [30] TR NM NM NM 4.80 (1.40, 15.80)M NM NM NM NM
Zauls [31] LF NM NM NM NM 0.75 (0.15, 3.85)U 0.55 (0.12, 2.44)U 0.64 (0.07, 5.88)U NM
Han [32] LR 1.90 (0.90, 4.00)U 1.90 (0.90, 3.80)U 0.60 (0.10, 2.40)U,DE NM 0.87 (0.48, 1.58)U 1.09 (0.61, 1.98)U,DE 1.98 (1.11, 3.53)M,DE NM
Millar [33] LR 2.48 (0.98, 6.29)M 1.93 (0.38, 9.75)M 3.94 (1.28, 12.11)M NM NM NM NM 1.20 (0.57, 2.55)U,DE
Millar [33] DM 2.87 (1.33, 6.22)M 1.83 (0.39, 8.64)M 3.27 (1.14, 9.40)M NM NM NM NM 2.57 (1.30, 5.06)U
Millar [33] LR + DM 2.71 (1.49, 4.90)M,DE 1.88 (0.61, 5.76)M,DE 3.89 (2.03, 7.44)M,DE NM NM NM NM 1.83 (1.10, 3.02)U,DE
Moran [34] LR NM NM NM 2.21 (0.63, 7.81)M NM NM 1.22 (0.30, 4.93)M NM
Bantema [34] LRR + DM NM NM NM 3.03 (1.37, 6.67)M NM NM NM NM
Wong [35] LR NM NM NM 3.30 (1.20, 9.60)U NM NM NM NM
Wong [35] DM 3.60 (1.10, 11.30)U 6.00 (1.60, 22.60)U 4.20 (1.10, 16.00)U NM NM NM NM NM
Wong [35] LR + DM 2.16 (0.85, 5.50)M 2.22 (1.08, 9.84)M 3.48 (1.22, 9.93)M NM NM NM NM NM
Kim [36] IBTR 1.55 (0.32, 7.51)M 0.55 (0.05, 6.34)M 1.17 (0.22, 6.26)M NM NM NM NM NM
Arvold [38] LR 2.10 (0.95, 4.80)M 5.20 (1.80, 15.00)M 3.90 (1.70, 9.00)M NM NM NM NM NM
Truong [39] LRR NM NM NM NM 1.29 (0.99, 1.69)M NM NM NM
Sharon [40] LR NM NM NM NM NM NM 1.93 (1.02, 3.65)M NM
Roos [41] LR NM NM NM NM 2.50 (0.42, 10.00)U,DE 1.11 (0.24, 5.00)U,DE 3.90 (0.80, 20.10)U 4.00 (0.90, 18.10)U
Yau [42] IBTR NM NM NM NM NM NM 2.19 (0.76, 6.35)U NM
Yau [42] DF NM NM NM NM NM NM 2.17 (0.99, 4.75)U NM
Yau [42] IBTR + DF NM NM NM NM NM NM 1.57 (1.26, 1.97)U,DE NM
Smith [43] SIBC NM NM NM NM NM 1.49 (1.00, 2.22)U NM NM
Silvestrini [44] LR NM NM NM NM 1.12 (0.42, 2.97)U,DE NM NM 1.75 (1.44, 2.11)U,DE
The source of HRs and 95% CIs is derived from univariate analysis (U), multivariate analysis (M) or data-extrapolated (DE).
CI, confidence interval; DE, data-extrapolated; DF, distant failure; DM, distant metastasis; ER, estrogen receptor; Her-2, human epidermal growth factor receptor 2; HR, hazard ratio; IBTR, ipsilateral breast tumor
recurrence; LA, Luminal A; LB, Luminal B; LF, local failure; LR, local recurrence or relapse; LRR, locoregional recurrence; NM, not mentioned; PR, progesterone receptor; SIBC, second ipsilateral breast cancer;
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studies [31,33,36]. The median time to follow-up is in
the range of 39 to 107 months.
A total of 20,890 patients (88.3%) received postoperative
radiotherapy (RT), including accelerated partial breast ir-
radiation, whole breast irradiation, or MammoSite brachy-
therapy. Adjuvant systemic therapy (AST) after BCS are
defined as hormone/endocrine therapy (HT) only, chemo-
therapy (CT) only, or both. The directly reported rates
range from 0.0% to 77.0% for HT and 0.0% to 66.4% for
CT. Excluding studies that did not mention the respective
rates of HT or CT, 6,288 patients (49.4%) underwent HT
and 4,817 patients (22.5%) accepted CT (Table 1).
Single-molecular subtypes and postoperative recurrence
Single-molecular subtypes are defined as the dichotom-
ous status of a single receptor or protein, which will be
excluded from the meta-analysis if less than three stud-
ies are found involved in. Altogether, four proteins (ER,
PR, Her-2, and p53) are included in analyses.
Six articles involved Her-2 typing [31,32,34,40-42]
(Figure 2C) and we found that Her-2 positive patients
had a significantly higher recurrence risk when compared
to Her-2 negative individuals in both overall merge(HR =
1.97, 95% CI: 1.41-2.75) and LR subtotal merge (HR =
1.93, 95% CI: 1.34-2.78). A significantly higher risk of
postoperative recurrence is also observed in p53 positive
patients by overall merge (HR = 1.78, 95% CI: 1.49 -2.12)
and LR subtotal merge (HR = 1.73, 95% CI: 1.44-2.07) in
three studies [33,41,44] (Figure 2D). Five studies focus on
ER typing [31,32,39,41,44], and no significant correlation
is found between ER typing and LR (HR = 1.21, 95% CI:
0.96-1.53) (Figure 2A). Similarly, four eligible studiesFigure 2 Forest plots for recurrence risk of single-molecular typing af
PR+ (B), Her-2+ vs. Her-2 - (C) and p53+ vs. p53- (D). Squares and horiz
The area of the squares correlates the weight and the diamonds represen
bias for the following comparisons: ER - vs. ER+ (a), PR - vs. PR+ (b), Her-2
progesterone receptor; Her-2, human epidermal growth factor receptor 2.involving PR typing [31,32,41,43] did not show a signifi-
cant result (HR = 1.29, 95% CI: 0.94-1.76) (Figure 2B).
Above pooled HRs and 95% CIs are calculated by the
fixed-effects model (Table 3).
Triple-molecular subtypes and postoperative recurrence
Triple-molecular subtypes are defined as the combin-
ation of dichotomous status of three receptors (ER, PR,
and Her-2), including Luminal A (ER + and/or PR + and
Her-2-), Luminal B (ER + and/or PR + and Her-2+),
Her-2 (ER- and PR- and Her-2+), and triple-negative
(ER- and PR- and Her-2-) [45].
By setting Luminal A as a baseline, the recurrence risk
of patients with Luminal B, Her-2, or triple-negative
subtypes are compared by overall and subtotal merge of
five studies [32,33,35,36,38] (Table 2). We found that in-
dividuals with Luminal B had a significantly higher risk
for total recurrence (HR = 2.23, 95% CI: 1.55 -3.19), LR
(HR = 2.05, 95% CI: 1.31-3.23) or DR (HR = 3.08, 95%
CI: 1.62-5.86) (Figure 3A). This significantly higher risk
is also observed in patients with Her-2 subtype by over-
all merge (HR = 2.26, 95% CI: 1.42-3.60), LR subtotal
merge (HR = 2.33, 95% CI: 1.35-4.02), and DR subtotal
merge (HR = 3.64, 95% CI: 1.33-9.97) (Figure 3B).
Triple-negative individuals also had significantly higher
risk of overall recurrence (HR = 2.90, 95% CI: 1.84 -4.58),
LR (HR = 2.64, 95% CI: 1.48-4.71), and DR (HR = 3.60,
95% CI: 1.57-8.25) (Figure 3C). Four studies focus on the
comparison between triple-negative and non-triple-
negative subtypes [30,34,35,37], and a significantly higher
recurrence risk is observed in patients with triple-negative
subtype by overall merge (HR = 3.19, 95% CI: 1.91-5.31)
and LR subtotal merge (HR = 3.31, 95% CI: 1.69-6.45)ter BCT in the following comparisons: ER - vs. ER+ (A), PR - vs.
ontal lines correspond to the study-specific HRs and 95% CIs, respectively.
t the summary HRs and 95% CIs. Begg's funnel plots for publication
+ vs. Her-2 - (c) and p53+ vs. p53- (d). ER, estrogen receptor; PR,




ER - vs. + PR - vs. + Her-2 + vs. - p53 + vs. -
N HR (95% CI) P N HR (95% CI) P N HR (95% CI) P N HR (95% CI) P
Overall 5 1.21 (0.96, 1.53)a 0.107 4 1.29 (0.94, 1.76)a 0.118 7 1.97 (1.41, 2.75)a <0.01 4 1.78 (1.49, 2.12)a <0.01
Local recurrence 5 1.21 (0.96, 1.53)a 0.107 4 1.29 (0.94, 1.76)a 0.118 6 1.93 (1.34, 2.78)a <0.01 3 1.73 (1.44, 2.07)a <0.01
Distant recurrence 0 - - 0 - - 1 2.17 (0.99, 4.75) - 1 2.57 (1.30, 5.06) -
Recurrence 0 - - 0 - - 1 1.57 (1.26, 1.97) - 1 1.83 (1.10, 3.02) -
Local recurrence is defined to include true recurrence (TR), local failure (LF), local recurrence or relapse (LR), ipsilateral breast tumor recurrence (IBTR), locoregional
recurrence (LRR), or second ipsilateral breast cancer (SIBC). Distant recurrence is defined to include distant metastasis (DM) or distant failure (DF). Recurrence is
defined to include any local and/or distant recurrence, which is the merge of LR and DR in the same study or not definitely mentioned.
aThe HRs and 95% CIs of enrolled studies are pooled by the fixed-effects model.
CI, confidence interval; ER, estrogen receptor; Her-2, human epidermal growth factor receptor 2; HR, hazard ratio; N, number of studies; PR, progesterone receptor.
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lated by the fixed-effects model (Table 4).
Publication bias
Unexpectedly, the comparison of TN vs. LA (Figure 3c)
shows obvious publication bias by Egger’s test (P = 0.021).
However in the other seven molecular typing compari-
sons, the shapes of funnel plots seem symmetrical and the
results of Egger’s test do not suggest any publication bias
(all P >0.05) (Figure 2a, b, c, d and Figure 3a, b, d).
Discussion
BC has become a major cause of morbidity and mortal-
ity in women [46]; there are an estimated 5.2 million BC
survivors worldwide [47]. A recent study reported that
the incidence of BC in the United States from 2000 to
2009 showed a recent increase, especially for early-stage
disease (in situ and localized) in non-Hispanic blacksFigure 3 Forest plots for the recurrence risk of triple-molecular typin
LA (B), TN vs. LA (C) and TN vs. non-TN (D). Squares and horizontal line
The area of the squares correlates the weight and the diamonds represent
bias for the following comparisons: LB vs. LA (a), Her-2 vs. LA (b), TN vs. LA
epidermal growth factor receptor 2; TN, triple-negative.and Asian/Pacific Islanders [48]. In addition, from 1976
to 2009, the incidence of advanced BC rose significantly
among young women in the US (from 1.53/100,000 to
2.9/100,000); this trend may be accelerating and seems
confined to women aged 25 to 39 years [49].
Currently, local excision combined with adjuvant RT
has been well-established as an optimal treatment strat-
egy for early-stage BC [2,11,50,51]. This may be an over-
treatment if RT is imposed on any patient after BCS.
Recurrence risk in a considerable proportion of patients
is sufficiently low, especially DCIS diagnosed through
screening of healthy women [52]. In contrast, for pa-
tients with high recurrence risk where only RT may be
insufficient, AST (HT and/or CT) should also be admin-
istered after BCS [30]. In our meta-analysis, 16 enrolled
studies display extreme difference in rates for RT (0% to
100%), HT (0% to 77%), and CT (0% to 66.4%) based on
the diversity of patient age, pathological types, clinicalg after BCT in the following comparisons: LB vs. LA (A), Her-2 vs.
s correspond to the study-specific HRs and 95% CIs, respectively.
the summary HRs and 95% CIs. Begg's funnel plots for publication
(c) and TN vs. non-TN (d). LB, Luminal B; LA, Luminal A; Her-2, human




LB vs. LA Her-2 vs. LA TN vs. LA TN vs. non-TN
N HR (95% CI) P N HR (95% CI) P N HR (95% CI) P N HR (95% CI) P
Overall 6 2.23 (1.55, 3.19)a <0.01 6 2.26 (1.42, 3.60)a 0.001 6 2.90 (1.84, 4.58)a <0.01 4 3.19 (1.91, 5.31)a <0.01
Local recurrence 4 2.05 (1.31, 3.23)a 0.002 4 2.33 (1.35, 4.02)a 0.002 4 2.64 (1.48, 4.71)a 0.001 3 3.31 (1.69, 6.45)a <0.01
Distant recurrence 2 3.08 (1.62, 5.86)a 0.001 2 3.64 (1.33, 9.97)a 0.012 2 3.60 (1.57, 8.25)a 0.002 0 - -
Recurrence 2 2.54 (1.54, 4.19)a <0.01 2 2.04 (0.93, 4.49)a 0.075 2 3.77 (2.17, 6.55)a <0.01 1 3.03 (1.37, 6.67) -
Local recurrence is defined to include true recurrence (TR), local failure (LF), local recurrence or relapse (LR), ipsilateral breast tumor recurrence (IBTR), locoregional
recurrence (LRR), or second ipsilateral breast cancer (SIBC). Distant recurrence is defined to include distant metastasis (DM) or distant failure (DF). Recurrence is
defined to include any local and/or distant recurrence, which is the merge of LR and DR in the same study or not definitely mentioned.
aThe HRs and 95% CIs of enrolled studies are pooled by the fixed-effects model.
CI, confidence interval; Her-2, human epidermal growth factor receptor 2; HR, hazard ratio; LA, Luminal A; LB, Luminal B; N, number of studies; TN, triple-negative.
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evaluation criteria are needed to identify patients at high
recurrence risk from those at low risk, and to help
choose a more precise postoperative treatment strategy
for patients undergoing BCS.
Towards this goal, consideration must be given to the
combination of underlying pathological and clinical char-
acteristics. Recent studies have shown that molecular
subtypes are prognostic for LR and DR after BCS, and im-
munohistochemical staining is often used to approxi-
mately identify these subtypes [18,19,53]. In this review,
we take both single-molecular and triple-molecular typing
into evaluation (Table 2). To our knowledge, this is the
first meta-analysis study to comprehensively assess the ef-
fect of molecular subtypes on recurrence after BCT.
Our meta-analysis shows that there are significant dif-
ferences in recurrence risk among various BC subtypes
after BCT. First, we analyzed the efficacy of single-
molecular subtypes. Although a slightly increased risk
has been found in both ER negative and PR negative pa-
tients, there is no significant effect on LR after BCT.
Only Her-2 positive patients display a significantly
higher risk for local and overall recurrence when com-
pared to Her-2 negative individuals (Table 3). It reveals
that Her-2 positive status could be used clinically as
an independent prognostic factor of high recurrence
risk, and the status of Her-2 is the most important in
the combined efficacy of triple-molecular subtypes. In
addition, overexpression of p53 (p53 positive) is presumed
to be a surrogate for TP53 mutations, which are associ-
ated with higher tumor grade [54]. Our results display that
p53 positive patients have a significantly increased risk for
overall recurrence and LR when compared to p53 negative
(low expression) individuals (Table 3). Thus, p53 positive
subtype should also be considered an important, inde-
pendent prognostic biomarker for indicating high recur-
rence risk. P53 positive individuals are more necessary to
accept adjuvant RT combined with or without AST and
will benefit more than those with p53 negative BC for pre-
venting postoperative recurrence because p53 positivesubtype also predicts better responsiveness to both RT
and AST [54]. Apart from the above mentioned four
biomarkers, we did not find any other receptor or pro-
tein that met our inclusion criteria. Although Ki67 is
generally accepted as one of the most important mole-
cules for BC typing and has been studied over a long
period of time [55], only one study was found focusing
on our subject [33].
Recently, more studies have focused on the combined
efficacy of ER, PR, and Her-2 receptors since the 12th St
Gallen International Breast Cancer Conference (2011)
Expert Panel adopted a new approach to BC classifica-
tion for therapeutic purposes based on the recognition
of intrinsic biological subtypes [55]. Therefore, we also
put emphasis on the relationship between triple-molecular
subtypes and recurrence risk after BCT. When compared
with Luminal A, Luminal B, Her-2, and triple-negative sub-
types all show significantly increased risk for both LR and
DR. All HR values for overall recurrence based on triple-
molecular typing are greater than 2.0, which can identify
patients with higher recurrence risk and shows more
clinical prediction value than analyses based on single-
molecular typing (Table 4). For example, the HR value
of LR (HR = 2.33) derived from triple-molecular com-
parison between Her-2 and Luminal A subtypes is larger
than the HR value of LR (HR = 1.93) derived from
single-molecular comparison between Her-2 positive
and Her-2 negative subtypes. Therefore, we concluded
that the clinical application of triple-molecular typing as
a biomarker can better distinguish high-risk individuals
compared to single-molecular typing.
Moreover, the comparison between triple-negative and
non-triple-negative subtypes shows the biggest risk dif-
ference for overall recurrence (HR = 3.19) and LR (HR =
3.31) among all molecular typing comparisons. When
setting Luminal A as a baseline, the HR value of triple-
negative subtype (HR = 2.90) remains larger than that of
Luminal B (HR = 2.23) or Her-2 subtypes (HR = 2.26)
for overall recurrence (Table 4). Previous studies have
shown that triple-negative receptor status is strongly
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young women more frequently suffer from triple-negative
tumors [57]. Thus, triple-negative subtype should be con-
sidered the biggest risk factor for recurrence and adjuvant
CT should be administered in BCT.
Some limitations of this meta-analysis should be ac-
knowledged. First, there are only three studies focused
on Asians [35,36,42] and none on Africans in this meta-
analysis, hindering comprehensive investigation of the
association between BC molecular typing and recurrence
risk after BCT. Second, the sample sizes of enrolled re-
searches (from 39 to 8,724) vary widely, and therefore
the statistical power or weight of each study is greatly
different, inevitably causing bias to varying degrees.
Third, the number of original studies focusing on this
topic is insufficient, especially studies related to DR risk.
Conclusions
Our meta-analysis represents a quantified synthesis of all
published studies and shows significant differences in re-
currence risk among various molecular subtypes after
BCT. Her-2 positive and p53 positive subtypes can be con-
sidered independent prognostic biomarkers for indicating
high LR risk, but triple-molecular biomarkers exhibit
higher clinical value than single-molecular biomarkers.
Moreover, triple-negative subtype shows the biggest risk
for overall recurrence and LR among all molecular sub-
types and adjuvant CT should be considered in BCT. Con-
sidering the insufficient number of original studies, further
research with different ethnicities is needed on this topic,
especially the intensity of association between molecular
typing and DR risk after BCT.
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